Vanguard Group’s Creative Medical Technology CELZ Stock Holding History

Vanguard Group’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$50.7K	Hold	25,868	–	–	﹤0.01%	4246
2025 Q3	$85.1K	Buy	25,868 +8,239	+47%	+$25.5K	﹤0.01%	4247
2025 Q2	$46.7K	Hold	17,629	–	–	﹤0.01%	4203
2025 Q1	$38.3K	Hold	17,629	–	–	﹤0.01%	4210
2024 Q4	$42.1K	Hold	17,629	–	–	﹤0.01%	4223
2024 Q3	$53.9K	Hold	17,629	–	–	﹤0.01%	4243
2024 Q2	$67.9K	Sell	17,629 -3	-0%	-$14	﹤0.01%	4266
2024 Q1	$91.9K	Buy	17,632 +3	+0%	+$14	﹤0.01%	4252
2023 Q4	$81.3K	Hold	17,629	–	–	﹤0.01%	4323
2023 Q3	$86.7K	Hold	17,629	–	–	﹤0.01%	4360
2023 Q2	$81.7K	Buy	17,629 +11,524	+189%	+$66.9K	﹤0.01%	4407
2023 Q1	$30.5K	Hold	6,105	–	–	﹤0.01%	4506
2022 Q4	$23.3K	Hold	6,105	–	–	﹤0.01%	4487
2022 Q3	$27K	Hold	6,105	–	–	﹤0.01%	4580
2022 Q2	$46K	Buy	6,105 +3,588	+143%	+$57.8K	﹤0.01%	4593
2022 Q1	$98K	Buy	+2,517	New	+$56K	﹤0.01%	4596

Other funds holding CELZ

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's CELZ Position: Q4 2025 in Review

Vanguard Group held its Creative Medical Technology (CELZ) position steady in Q4 2025 at 25,868 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4246.

Vanguard Group first reported a position in CELZ in Q1 2022 and has held it in 16 quarters since. The position peaked at $98K in Q1 2022. 14 funds tracked by Wall St. Rank hold CELZ as of Q4 2025.

Vanguard Group held 25,868 shares of Creative Medical Technology worth $50.7K as of Q4 2025.
Vanguard Group left its Creative Medical Technology share count unchanged in Q4 2025.
Creative Medical Technology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4246 holding.
Vanguard Group first reported a position in Creative Medical Technology in Q1 2022 and has held it in 16 quarters since.
Vanguard Group's Creative Medical Technology position peaked at $98K in Q1 2022.
14 funds tracked by Wall St. Rank held Creative Medical Technology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.